Repaglinide - Prandial glucose regulator: A new class of oral antidiabetic drugs

Diabetic Medicine

Volumn 15, Issue SUPPL. 4, 1998, Pages

  Owens, David R ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Clinical pharmacology; First line monotherapy; Glycaemic control; Prandial; Repaglinide; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLYCOSYLATED HEMOGLOBIN; REPAGLINIDE;

ARTICLE; BLOOD GLUCOSE MONITORING; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEART DISEASE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CARBAMATES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; EATING; FASTING; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC CLEARANCE RATE; PIPERIDINES; POSTPRANDIAL PERIOD;

EID: 0031790685     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9136(1998120)15:4+3.3.co;2-k     Document Type: Article

References (16)

1. Grell W, Mark M, Luger P, Nar H, Wittnedben H, Muller P. Repaglinide differs structurally from the sulphonylureas glibenclamide and glimepiride. Diabetologia 1997; 40 (Suppl 1): A321.
2. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium channels and cystosolic calcium levels in β TC3 cells and rat pancreatic β cells. Diabetologia 1995; 38 (9): 1025-1032.
3. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
4. Viñambres C, Villanueva-Peñacarrillo ML, Malaisse WJ. Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets. Pharmacol Res 1996; 34 (1-2): 83-85.
5. Bakkali-Nadi A. Mailaisse-Lagae F, Malaisse WJ. Insulinotropic action of meglitinide analogs; concentration-response relationship and nutrient dependency. Diabetes Res 1994; 27 (2): 81-87.
6. Mark M, Grell W. Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs. Brit J Pharmacol 1997; 121: 1597-1604.
7. Ladrière L, Malaisse-Lagae F, Fuhlendorff J, Malaisse WJ. Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats. Eur J Pharmacol 1997; 335 (2-3): 227-234.
8. Oliver S, Ahmad S, Hatorp V. Pharmacokinetics and bioavailability of repaglinide, a new OHA for patients with NIDDM. Diabetologia 1997; 40 (Suppl 1): A320.
9. Robling MR, Dolben J, Luzio SD, Godtfredsen S, Owens DR. Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes mellitus (NIDDM). Brit J Clin Pharmacol 1992; 34: 173P.
10. Damsbo P, Andersen PH, Lund S, Pørksen N. Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing. Diabetes 1997; 46: 34A.
11. Tronier B, Marbury TC, Damsbo P, Windfeld K. A new oral hypoglycaemic agent, repaglinide, minimises risk of hypoglycaemia in well-controlled NIDDM patients. Diabetologia 1995; 38: A752.
12. Landgraf R, Bilo HJG. Repaglinide vs. glibenclamide: a 14-week efficacy and safety comparison. Diabetologia 1997; 40 (Suppl 1): A321.
13. Wolffenbuttel BHR, Nijst L, Sels JPJE, Mcnheere PPCA, Müller PG, Nieuwenhuijzen Kruseman AC. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45: 113-116.
14. Moses R, Slobodniuk R, Donnelly T, Moffitt P, Boyages S, Colagiuri S, Kidson W, Carter J. Additional treatment with repaglinide provides significant improvement in glycaemic control in NIDDM patients poorly controlled on metformin. Diabetes 1997; 46: 93A.
15. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
16. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metaformin on complications in overweight patients with Type 2 Diabetes (UKPDS 34). Lancet 1998; 352: 854-865.